Report Overview

The global osteoarthritis therapeutics market size stood at around USD 6.8 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Osteoarthritis is the most common form of arthritis that causes pain, swelling, and reduced motion in the joints. The geriatric population and over-weighted individuals are at higher risks of osteoarthritis. The growing geriatric population, rising prevalence of osteoarthritis, and increasing per capita healthcare expenditure will drive the market growth during the forecast period. In 2015, according to the National Institutes of Health, the American geriatric population is expected to nearly double from 48 million in 2015 to 88 million by 2050. However, low per capita income in the developing countries and side effects of the treatment procedures will restrain the market growth during the forecast period



Market Growth Drivers

The growth of the global osteoarthritis treatment market is due to the rising geriatric population, increasing incidence of osteoarthritis, and rising demand for minimally invasive surgical procedures

The global increase in the geriatric population leads to a higher incidence of osteoarthritis (OA) among the aged population. It is the most common type of joint disease, found in people aged more than 65 years, which is accompanied by mortality and decreased quality of life. Osteoarthritis (OA) is one of the most common causes of pain and disability in the elderly population and is driving the growth of the market

In addition, there are many osteoarthritis research studies ongoing on cartilage, the lubricating surface in the joint. The work is being done to re-grow the cartilage using stem cells treated with molecules to aid their growth. Hence, ongoing research and rising government support help in creating new opportunities for the growth of the osteoarthritis treatment market